CN114072396A - 作为dna-pk抑制剂的喹啉和噌啉衍生物 - Google Patents

作为dna-pk抑制剂的喹啉和噌啉衍生物 Download PDF

Info

Publication number
CN114072396A
CN114072396A CN202080045905.4A CN202080045905A CN114072396A CN 114072396 A CN114072396 A CN 114072396A CN 202080045905 A CN202080045905 A CN 202080045905A CN 114072396 A CN114072396 A CN 114072396A
Authority
CN
China
Prior art keywords
compound
reaction
isomer
pharmaceutically acceptable
reduced pressure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080045905.4A
Other languages
English (en)
Other versions
CN114072396B (zh
Inventor
陈新海
陈兆国
张丽
胡伯羽
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medshine Discovery Inc
Original Assignee
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medshine Discovery Inc filed Critical Medshine Discovery Inc
Publication of CN114072396A publication Critical patent/CN114072396A/zh
Application granted granted Critical
Publication of CN114072396B publication Critical patent/CN114072396B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/28—Cinnolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Abstract

本发明公开了式(I)所示化合物、其异构体或其药学上可接受的盐，并公开了其在制备治疗与DNA‑PK激酶抑制剂相关疾病药物中的应用。

Description

PCT国内申请，说明书已公开。

Claims (18)

  1. PCT国内申请，权利要求书已公开。
CN202080045905.4A 2019-06-27 2020-06-24 作为dna-pk抑制剂的喹啉和噌啉衍生物 Active CN114072396B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN2019105687380 2019-06-27
CN201910568738 2019-06-27
CN202010076183 2020-01-23
CN2020100761830 2020-01-23
CN2020102093720 2020-03-23
CN202010209372 2020-03-23
PCT/CN2020/098198 WO2020259613A1 (zh) 2019-06-27 2020-06-24 作为dna-pk抑制剂的喹啉和噌啉衍生物

Publications (2)

Publication Number Publication Date
CN114072396A true CN114072396A (zh) 2022-02-18
CN114072396B CN114072396B (zh) 2024-02-02

Family

ID=74059859

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080045905.4A Active CN114072396B (zh) 2019-06-27 2020-06-24 作为dna-pk抑制剂的喹啉和噌啉衍生物

Country Status (6)

Country Link
US (1) US20220267310A1 (zh)
EP (1) EP3992189A4 (zh)
JP (1) JP7313492B2 (zh)
KR (1) KR20220027183A (zh)
CN (1) CN114072396B (zh)
WO (1) WO2020259613A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022143671A1 (zh) * 2020-12-28 2022-07-07 南京明德新药研发有限公司 吗啉取代的苯并嘧啶类化合物的晶型及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105358552A (zh) * 2013-05-11 2016-02-24 默克专利股份公司 芳基喹唑啉
WO2018114776A1 (en) * 2016-12-19 2018-06-28 Merck Patent Gmbh Combination of a protein kinase inhibitor and an additional chemotherapeutic agent
WO2018178133A1 (en) * 2017-03-30 2018-10-04 Merck Patent Gmbh Solid form of (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol
CN111909144A (zh) * 2019-05-10 2020-11-10 山东轩竹医药科技有限公司 喹唑啉类dna-pk抑制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110446706B (zh) * 2017-03-30 2023-05-16 默克专利股份公司 (s)-[2-氯-4-氟-5-(7-吗啉-4-基喹唑啉-4-基)苯基]-(6-甲氧基-哒嗪-3-基)甲醇的晶型
SG10202110707UA (en) * 2017-03-30 2021-11-29 Merck Patent Gmbh Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer
EP4286007A3 (en) * 2017-03-30 2024-04-10 Merck Patent GmbH Pharmaceutical formulation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105358552A (zh) * 2013-05-11 2016-02-24 默克专利股份公司 芳基喹唑啉
WO2018114776A1 (en) * 2016-12-19 2018-06-28 Merck Patent Gmbh Combination of a protein kinase inhibitor and an additional chemotherapeutic agent
WO2018178133A1 (en) * 2017-03-30 2018-10-04 Merck Patent Gmbh Solid form of (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol
CN111909144A (zh) * 2019-05-10 2020-11-10 山东轩竹医药科技有限公司 喹唑啉类dna-pk抑制剂

Also Published As

Publication number Publication date
JP2022540360A (ja) 2022-09-15
EP3992189A4 (en) 2022-12-07
US20220267310A1 (en) 2022-08-25
CN114072396B (zh) 2024-02-02
WO2020259613A1 (zh) 2020-12-30
JP7313492B2 (ja) 2023-07-24
EP3992189A1 (en) 2022-05-04
KR20220027183A (ko) 2022-03-07

Similar Documents

Publication Publication Date Title
CN104910161B (zh) 作为jak抑制剂的吡唑并嘧啶化合物和方法
US11434232B2 (en) ATR inhibitor and application thereof
CN108473502A (zh) 用于治疗癌症的4,6二氢吡咯并[3,4-c]吡唑-5(1h)-腈衍生物
TW201823249A (zh) Ｍｅｎｉｎ－ｍｌｌ相互作用之稠合二環抑制劑
CN106170288A (zh) 药物化合物
WO2017035753A1 (zh) 2-芳胺基吡啶、嘧啶或三嗪衍生物及其制备方法和用途
CN113321654B (zh) 作为激酶抑制剂的稠合吡啶酮类化合物
JP7474319B2 (ja) ヘテロ環式アミド化合物及びその製造方法並びに使用
CN109867676A (zh) 一种吡咯并嘧啶衍生的化合物、药物组合物以及其用途
WO2019201297A1 (zh) 作为rho激酶抑制剂的苯并吡唑类化合物
WO2020233669A1 (zh) 含吲哚类衍生物抑制剂、其制备方法和应用
JP7260718B2 (ja) ジアザインドール誘導体及びそのＣｈｋ１阻害剤としての使用
CN115776888A (zh) 含大环醚的吲哚衍生物作为mcl-1抑制剂
WO2021204111A1 (zh) 作为dna-pk抑制剂的氨基嘧啶化合物及其衍生物
TW202110848A (zh) 取代的稠合雙環類衍生物、其製備方法及其在醫藥上的應用
WO2020207476A1 (zh) 一种吡唑并吡嗪衍生的化合物、药物组合物以及其用途
CN109867675A (zh) 一种吡咯并嘧啶衍生的化合物、药物组合物以及其用途
CN114072396A (zh) 作为dna-pk抑制剂的喹啉和噌啉衍生物
CN115667258A (zh) 氟代吡咯并吡啶类化合物及其应用
TW202400576A (zh) 嘧啶類化合物、其製備方法及其醫藥用途
WO2022199635A1 (zh) 苄氨基喹唑啉类衍生物
WO2023280317A1 (zh) 苄氨基三并环类化合物及其应用
JP7358372B2 (ja) イミダゾピロロン化合物及びその使用
CN114728986A (zh) 作为mcl-1抑制剂的大环磺酰基衍生物
WO2021083011A1 (zh) 桥环并醛基吡啶衍生物及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40060748

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant